A 68-year-old man with a 40-pack-year smoking history presents with painless jaundice, weight loss of 8 kg over 3 months, and epigastric pain radiating to the back. CT pancreas protocol shows a firm white-tan mass in the pancreatic head (marked **A**) with distal common bile duct stricture and dilated proximal CBD. The mass demonstrates ≤180° contact with the superior mesenteric vein with maintained patency. Which of the following is the most appropriate next step in management according to current NCCN guidelines?
A. Neoadjuvant mFOLFIRINOX followed by reassessment for resectability
B. Immediate palliative chemotherapy (gemcitabine monotherapy) followed by best supportive care
C. Endoscopic ultrasound-guided fine-needle aspiration for tissue diagnosis only, with no further intervention planned
D. Pancreaticoduodenectomy (Whipple procedure) with adjuvant mFOLFIRINOX in a fit patient
Explanation
Why Pancreaticoduodenectomy (Whipple procedure) with adjuvant mFOLFIRINOX is right
The firm white-tan mass in the pancreatic head (A) with ≤180° contact with the SMV and maintained patency meets NCCN criteria for RESECTABLE pancreatic ductal adenocarcinoma. The classic presentation of painless obstructive jaundice, weight loss, and epigastric pain radiating to the back (indicating retroperitoneal/perineural invasion) is typical of pancreatic head adenocarcinoma. For resectable disease in a fit patient, pancreaticoduodenectomy (Whipple procedure)—resecting the pancreatic head, duodenum, distal CBD, gallbladder, and proximal jejunum with reconstruction—is the gold standard curative intent approach. Adjuvant mFOLFIRINOX significantly extends overall survival in fit patients (PRODIGE 24 trial), making this the standard of care per NCCN 2024 guidelines for pancreatic adenocarcinoma.
Why each distractor is wrong
Immediate palliative chemotherapy (gemcitabine monotherapy) followed by best supportive care: This represents a palliative approach appropriate only for metastatic or unresectable locally advanced disease. The patient's imaging shows resectable disease with no evidence of distant metastases, making palliative intent inappropriate and abandoning the only curative modality (surgery).
Neoadjuvant mFOLFIRINOX followed by reassessment for resectability: While neoadjuvant therapy is increasingly favored for borderline resectable disease (to improve R0 resection rates and treat micrometastases), this patient's tumor meets criteria for resectable disease. Neoadjuvant therapy in truly resectable disease may delay surgery and increase perioperative risk without proven survival benefit; upfront surgery followed by adjuvant therapy is standard for resectable PDAC.
Endoscopic ultrasound-guided fine-needle aspiration for tissue diagnosis only, with no further intervention planned: While EUS-FNA is useful for tissue diagnosis in small lesions or when diagnosis is uncertain, this patient has a classic presentation and imaging highly suggestive of pancreatic head adenocarcinoma. Performing diagnostic EUS-FNA without a treatment plan represents a delay in definitive management and denies the patient the only potentially curative intervention (resection).
High-YieldNEET PG
Pancreatic head adenocarcinoma presenting with painless obstructive jaundice, weight loss, and epigastric pain radiating to the back in a resectable patient (≤180° vascular contact with patent SMV/PV, no involvement of celiac/SMA/hepatic artery) requires upfront pancreaticoduodenectomy followed by adjuvant mFOLFIRINOX in fit patients for best survival outcomes.
